New study aims to predict who will respond to breast cancer therapy
NCT ID NCT07597642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at tumor samples from 55 women with early-stage breast cancer to find early signs of whether chemo-immunotherapy is working. By analyzing individual cells before, during, and after treatment, researchers hope to identify markers that predict response or resistance. The goal is to help doctors tailor treatments more effectively in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Ospedale San Raffaele
Milan, Lombardy, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smartphone program ease Chemo's emotional toll?
- Could fewer heart tests be safer for breast cancer patients?
- Blood test could revolutionize breast cancer monitoring
- Tech trio aims to help breast cancer survivors remember daily pills
- New program aims to protect cancer Patients' hearts during treatment
- Freezing, not cutting: new study tests cryoablation for breast cancer in seniors